Sort
4,870 grants matching “glp 1”
Portable pneumatic driver for counterpulsation therapy
$752,574Paul A Spence · Scr, Inc. · R44 · FY2009 · HL
Role of Activin Type II Receptor Signaling in Muscle Hypertrophy, Obesity, and Weight Loss
$752,121Joseph A. Baur · University Of Pennsylvania · R01 · FY2025 · DK
Nitrite dependent protection against Cl2 gas toxicity_role of chlorinated lipids
$751,909Rakesh Pravinchandra Patel · University Of Alabama At Birmingham · U01 · FY2017 · ES
Neuroprotective role of GLP-1 receptor agonists
$751,361Nigel H. Greig · National Institute On Aging · ZIA · FY2016 · AG
PAR2 Pepducins as a Novel Treatment of Idiopathic Pulmonary Fibrosis
$750,502Athan Kuliopulos · Oasis Pharmaceuticals · R42 · FY2019 · HL
Progressing the Pre-clinical development of P8 for Alzheimer's Disease
$750,000Nazneen N Dewji · Cenna Biosciences, Inc. · R44 · FY2017 · AG
Dihydroceramide Desaturase-1 Inhibitors for Treatment of Diabetes and Other Metabolic Diseases
$749,999Jeremy Blitzer · Potrero Hill Therapeutics, Inc. · R44 · FY2018 · DK
Dihydroceramide Desaturase-1 Inhibitors for Treatment of Diabetes and Other Metabolic Diseases
$749,999Jeremy Blitzer · Potrero Hill Therapeutics, Inc. · R44 · FY2019 · DK
CometChip: Development of a high throughput DNA damage assay in hepatocytes
$749,975Leslie Recio · Integrated Laboratory Systems, Llc · U44 · FY2018 · ES
"Insulin Affordability: Unpacking the Impact of the Inflation Reduction Act on Diabetes Outcomes in Medicare."
$749,566Kasia Joanna Lipska · Yale University · R01 · FY2025 · DK
Development of Filociclovir for the Treatment of Ocular Adenoviral Infections and Keratoconjunctivitis
$749,526Terry L Bowlin · Microbiotix, Inc · R44 · FY2021 · EY
Ambient light activatable opsin based therapy for age-related macular degeneration
$749,517Samarendra Kumar Mohanty · Nanoscope Technologies, Llc · R44 · FY2021 · EY
Role of GLUT1 in diabetic cardiomyopathy
$749,360Konstantinos Drosatos · University Of Cincinnati · R01 · FY2025 · HL
Automated Intestinal Electrical Stimulation for Diabetes
$749,185Jiande Chen · Transtimulation Research, Inc. · R42 · FY2020 · DK
Automated Intestinal Electrical Stimulation for Diabetes
$749,185Jiande Chen · Transtimulation Research, Inc. · R42 · FY2019 · DK
Effects of GLP-l receptor agonists on cardiometabolic alterations in HIV-associated lipohypertrophy
$748,650Grace A McComsey · Case Western Reserve University · R01 · FY2023 · DK
Drug Development of GLP-1 receptor agonists
$748,585Josephine Egan · National Institute On Aging · ZIA · FY2016 · AG
IND-Enabling Studies of ZB716, an Orally Bioavailable SERD
$748,371Guangdi Wang · Zenopharm, Llc · R44 · FY2018 · CA
CV Benefits and Safety of Glucose-Lowering Therapies in Adults with Diabetes
$748,336Patrick J O'Connor · Healthpartners Institute · R01 · FY2016 · HL
Rapid Magnetomotive Thrombolysis for Stroke
$748,265Michael Anthony Tones · Pulse Therapeutics, Inc. · R44 · FY2016 · NS
Progressing the Pre-clinical development of P8 for Alzheimer's Disease
$747,850Nazneen N Dewji · Cenna Biosciences, Inc. · R44 · FY2018 · AG
Unraveling the neural mechanisms for satiety and weight loss by GLP1-based drugs
$747,133Amber L Alhadeff · Monell Chemical Senses Center · R01 · FY2025 · DK
RNAi Therapy for Spinocerebellar Ataxia Type 1
$746,997Beverly L Davidson · Children'S Hosp Of Philadelphia · UH3 · FY2023 · NS
Saracatinib and 1400W Counteract Nerve Agents-Induced Long-Term Neurotoxicity
$746,842Thimmasettappa Thippeswamy · Iowa State University · U01 · FY2022 · NS
CV Benefits and Safety of Glucose-Lowering Therapies in Adults with Diabetes
$746,462Patrick J O'Connor · Healthpartners Institute · R01 · FY2015 · HL